Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative Medicine

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1513950

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1513950

Mesenchymal Stem Cells (MSC)

PUBLISHED:
PAGES: 202 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Mesenchymal Stem Cells (MSC) Market to Reach US$10.6 Billion by 2030

The global market for Mesenchymal Stem Cells (MSC) estimated at US$4.7 Billion in the year 2023, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2023-2030. Bone Marrow-sourced MSC, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Adipose Tissues-sourced MSC segment is estimated at 14.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Mesenchymal Stem Cells (MSC) Market - Key Trends and Drivers Summarized

Mesenchymal stem cells (MSCs), a type of adult stem cell found in various tissues such as bone marrow, adipose tissue, and umbilical cord tissue, hold significant promise for regenerative medicine and therapeutic applications across a spectrum of medical conditions. These cells are prized for their ability to self-renew and differentiate into a variety of cell lineages, including bone, cartilage, muscle, and nerve cells. Their potential is particularly compelling because they can evade immune rejection, a critical factor that enhances their suitability for clinical applications. The ability of MSCs to differentiate is influenced by various factors, including the source of the cells and the conditions under which they are cultured. This process is governed by complex genetic and epigenetic mechanisms that regulate their activation, proliferation, and maturation.

MSCs also exhibit immunomodulatory properties that are crucial for suppressing immune responses and fostering tissue repair, making them valuable in the treatment of autoimmune diseases, spinal cord injuries, and cardiovascular diseases. They promote angiogenesis and tissue regeneration, underscoring their importance in managing diverse medical conditions. MSCs are sourced from a range of tissues, each offering unique advantages and challenges in terms of isolation and expansion. However, their clinical application is hindered by challenges such as cellular heterogeneity, variability, and the need for quality control. To harness the therapeutic potential of MSCs effectively, it is essential to develop standardized methodologies and conduct rigorous safety evaluations.

In the oncological arena, MSCs present a dual role. They have been shown to contribute to tumor growth by promoting angiogenesis, immune evasion, and creating a tumor-supportive microenvironment. Conversely, they exhibit anti-tumor properties, deploying cytokines and other cytotoxic elements to target cancer cells. This dual nature necessitates a nuanced understanding of MSC behavior to optimize their therapeutic use in cancer treatment. Researchers are exploring innovative strategies to leverage MSCs as delivery vehicles for anti-cancer agents, transforming them into 'Trojan horses' that can carry therapeutic payloads directly to tumors. The combination of MSCs with biomaterials, which can scaffold the cells and control the release of therapeutic agents, presents a promising avenue to overcome current therapeutic limitations and enhance the efficacy of cancer treatments.

Select Competitors (Total 56 Featured) -

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.
Show more
Product Code: MCP-7815

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Mesenchymal Stem Cells (MSC) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Regenerative Medicine Advances Propel Demand for Mesenchymal Stem Cells
    • Aging Global Population Drives Growth in MSC-Based Therapies
    • Technological Breakthroughs in Stem Cell Proliferation and Preservation Enhance MSC Therapeutic Viability
    • Expanding Clinical Trials Spotlight Efficacy of MSCs in Diverse Diseases
    • Rising Prevalence of Autoimmune Diseases Accelerates MSC Research and Applications
    • Growing Investment in Biotechnology Strengthens the Business Case for MSC Development
    • Collaboration between Academia and Industry Spurs Innovations in MSC Research
    • Enhanced Delivery Techniques Improve MSC Therapeutic Outcomes
    • Personalized Medicine Trends Catalyze Targeted MSC Therapy Developments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2024 & 2030
    • TABLE 113: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!